Cardiovascular Medicines · LP-045
Amlodipine Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-045Cardiovascular Medicines
- Generic identity
- AmlodipineTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-045
- Generic identity
- Amlodipine
- Presentation
- Tablet
- Catalogue strength
- 5 mg; 10 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: amlodipine.
- Dosage form: tablet.
- Proposed strengths: 5 mg and 10 mg.
- General proposed pack: blister 10 × 10 tablets.
Layer 02 · Unresolved product-specific fields
- Final formulation, score/divisibility and exact SKU mapping.
- Approved indication, dosing, contraindications/warnings and population information.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 5 mg | Tablet | — | General blister pack | Final tablet specification and approved label are not supplied. |
| B | 10 mg | Tablet | — | General blister pack | Final tablet specification and approved label are not supplied. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Amlodipine is a calcium-channel blocker that relaxes blood vessels. It is used in selected management plans for high blood pressure and angina. Its role is ongoing control rather than immediate treatment of an acute episode of severe chest pain. This profile provides general ingredient education; it does not establish a Luang Pharma approved indication, demonstrate cardiovascular outcomes for a particular product or replace individualized prescribing advice.
Clinical context and therapeutic role
Blood-pressure management begins with reliable measurements, assessment of overall cardiovascular risk and attention to other medical conditions. A clinician determines whether amlodipine is suitable alone or with other medicines. For angina, the diagnosis and a separate plan for acute symptoms are important. Follow-up can assess blood pressure, dizziness and ankle swelling. An improvement in a measurement should not prompt unsupervised dose changes or discontinuation of prescribed treatment.
Selected safety context
Ankle swelling, flushing, headache, dizziness and palpitations can occur. Marked low blood pressure or fainting needs review. Significant liver disease, heart conditions and interacting medicines may influence suitability. Severe or worsening chest pain should be treated as an urgent clinical problem rather than attributed automatically to the medicine. A serious allergic reaction needs emergency care. The product strength alone does not confirm that a tablet can be split to create another presentation.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified clinician should review the cardiovascular indication, blood pressure or pulse where relevant, organ function and interacting medicines. Monitoring and treatment changes must be linked to the individual care plan and the authorized product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification/formulation.
Approved label and patient information.
Registration/market-status evidence.
Manufacturing-site and release documentation as applicable.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B06 checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: AmlodipineArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-045.
Professional enquiries
Request product-specific evidence for LP-045.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.